Tumor maligno com diferenciação glandular originando-se predominantemente da mucosa de Barrett no terço inferior do esôfago. Exemplos raros de adenocarcinoma esofágico derivado de mucosa gástrica ectópica na parte superior do esôfago também foram relatados. Grosso modo, os adenocarcinomas esofágicos são semelhantes aos carcinomas espinocelulares esofágicos. Microscopicamente, os adenocarcinomas que surgem no contexto do esôfago de Barrett são tipicamente papilares e/ou tubulares. O prognóstico é ruim.
Introdução
O que você precisa saber de cara
O **adenocarcinoma do esôfago** é um tumor maligno que afeta principalmente a parte inferior do esôfago, frequentemente ligado ao histórico de refluxo e alterações na mucosa. As pessoas afetadas costumam sentir desconforto no peito, tosse, náuseas e vômitos decorrentes da evolução do tumor. Na rede pública do Brasil, o atendimento ocorre no âmbito do protocolo de carcinoma de esôfago, sendo as condutas definidas conforme a autonomia técnica de cada serviço credenciado. Novas abordagens e medicamentos estão sob constante investigação científica em ensaios clínicos abertos no mundo e no país.
Tumor maligno com diferenciação glandular originando-se predominantemente da mucosa de Barrett no terço inferior do esôfago. Exemplos raros de adenocarcinoma esofágico derivado de mucosa gástrica ectópica na parte superior do esôfago também foram relatados. Grosso modo, os adenocarcinomas esofágicos são semelhantes aos carcinomas espinocelulares esofágicos. Microscopicamente, os adenocarcinomas que surgem no contexto do esôfago de Barrett são tipicamente papilares e/ou tubulares. O prognóstico é ruim.
Tem tratamento?
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 1 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 10 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
1 gene identificado com associação a esta condição. Padrão de herança: Not applicable.
Glioma
Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.
Medicamentos aprovados (FDA)
4 medicamentos encontrados nos registros da FDA americana.
Variantes genéticas (ClinVar)
58 variantes patogênicas registradas no ClinVar.
Vias biológicas (Reactome)
30 vias biológicas associadas aos genes desta condição.
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Adenocarcinoma do esôfago
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
Com ensaio aberto em 36 países. O ponto verde marca onde há vaga agora.
🟢 Recrutando agora
72 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
361 ensaios clínicos encontrados, 107 ativos.
Publicações mais relevantes
Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.
To compare camrelizumab plus capecitabine and oxaliplatin followed by camrelizumab plus apatinib (camre+CAPOX followed by camre+apa), CAPOX alone, and camrelizumab plus CAPOX followed by camrelizumab (camre+CAPOX followed by camre) as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma. Randomised, open label, phase 3 study. 75 hospitals in China, 13 March 2019 to 16 August 2021. 885 adults (≥18 years) with previously untreated, human epidermal growth factor receptor 2 (HER2) negative, unresectable, locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Patients were randomised (2:2:1) to receive camre+CAPOX followed by camre+apa, CAPOX only, or camre+CAPOX followed by camre, stratified by Eastern Cooperative Oncology Group performance status, peritoneal metastasis, and programmed death ligand 1 (PD-L1) combined positive score. Assignment to camre+CAPOX followed by camre was introduced midway through enrolment. The primary endpoint was overall survival for camre+CAPOX followed by camre+apa versus CAPOX alone in the PD-L1 positive population (combined positive score >1) and the overall population who received at least one dose of study drug. Comparisons of camre+CAPOX followed by camre versus CAPOX alone and of camre+CAPOX followed by camre+apa versus camre+CAPOX-camre were descriptive. Safety was assessed in all patients who received at least one dose of study drug. 352 patients received camre+CAPOX followed by camre+apa, 349 received CAPOX alone, and 177 received camre+CAPOX followed by camre. At the time of data cut off, 454 of 592 (76.7%) deaths had occurred in the PD-L1 positive population and 709 of 878 (80.8%) in the overall population. Overall survival was longer with camre+CAPOX followed by camre+apa than with CAPOX alone in the PD-L1 positive population (median 15.0 v 12.5 months; hazard ratio 0.80 (95% CI 0.65 to 0.98); one sided P=0.02) and in the overall population (median 13.5 v 12.1 months; hazard ratio 0.80 (0.68 to 0.94); one sided P=0.004). Use of camre+CAPOX followed by camre also showed longer overall survival versus CAPOX in the PD-L1 positive population (median 15.3 v 12.5 months; hazard ratio 0.76 (0.58 to 0.97); one sided nominal P=0.01) and overall population (median 14.2 v 12.1 months; hazard ratio 0.80 (0.65 to 0.98); one sided nominal P=0.02). No overall survival benefit was observed with camre+CAPOX followed by camre+apa versus camre+CAPOX followed by camre. Treatment related adverse events of grade ≥3 occurred in 239 of 352 (67.9%) patients in the camre+CAPOX followed by camre+apa group, 158 of 349 (45.3%) in the CAPOX alone group, and 83 of 177 (46.9%) in the camre+CAPOX followed by camre group. Initial treatment with camrelizumab plus CAPOX followed by camrelizumab based maintenance was associated with longer overall survival than CAPOX alone in human epidermal growth factor receptor 2 (HER2) negative, unresectable, locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Exploratory comparisons between the two camrelizumab based regimens showed no additional survival benefit, with higher rates of treatment related adverse events of grade ≥3 and treatment discontinuations when apatinib was added during maintenance. ClinicalTrials.gov NCT03813784.
Novel Methylation-Based Model for Accurate Diagnosis of Upper Mediastinal Lymph Node Metastasis in Esophagogastric Junction Adenocarcinoma.
Even after surgical resection, the prognosis is poor for patients with esophagogastric junction adenocarcinoma who develop upper mediastinal lymph node metastasis. Moreover, the current preoperative diagnostic accuracy for upper mediastinal lymph node metastasis remains inadequate, which complicates treatment planning. To enhance diagnostic precision and facilitate personalized therapeutic strategies, we aimed to develop a novel diagnostic model that integrates a DNA methylation panel with conventional clinical parameters. First, genome-wide methylation profiling of 69 tumors identified seven CpG sites significantly associated with upper mediastinal lymph node involvement. We then evaluated a methylation panel based on these markers in two independent cohorts comprising a total of 133 treatment-naïve patients. The methylation panel alone achieved moderate diagnostic performance (AUC 0.71, 95% CI 0.52-0.91), whereas its integration with clinical data substantially improved accuracy (training cohort: AUC 0.87, 95% CI 0.75-0.99). Applying the same model formula to an independent pretreatment validation cohort confirmed its robustness (AUC 0.85, 95% CI 0.70-1.00). Furthermore, the methylation panel was identified as an independent prognostic factor for overall survival (p < 0.01). Finally, to facilitate clinical implementation, the integrated model was formalized as a nomogram. In summary, this novel diagnostic model enables highly accurate detection of upper mediastinal lymph node metastasis in esophagogastric junction adenocarcinoma, with the potential to optimize treatment decisions and reduce the need for invasive procedures, thereby contributing to precision oncology.
Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: Current Status, Challenges, and Future Perspectives.
Gastric cancer remains a leading cause of cancer-related mortality worldwide, with locally advanced gastric/gastroesophageal junction adenocarcinoma posing significant therapeutic challenges. Neoadjuvant therapy has emerged as a critical strategy to improve surgical outcomes and long-term survival by reducing tumor burden and eradicating micrometastases. This systematic review integrates evidence from more than 100 clinical trials and 20 meta-analyses published in recent years. It focuses on new advances in neoadjuvant therapies for gastric cancer, including chemotherapy, radiotherapy, immunotherapy, and targeted therapies, while highlighting emerging combination strategies and unresolved clinical dilemmas.
Efficacy and safety of cadonilimab combined with chemotherapy for gastric or gastroesophageal junction adenocarcinoma: a single-arm meta-analysis.
Immune checkpoint inhibitors (ICIs) combined with chemotherapy have become an important area of clinical investigation in the gastric cancer (GC) and gastroesophageal junction cancer (GEJC). In recent years, bispecific antibody therapies have been increasingly explored, including cadonilimab, a programmed death-1/cytotoxic T-lymphocyte-associated antigen 4 (PD-1/CTLA-4) bispecific antibody. Several phase II studies have reported early signals of antitumor activity with cadonilimab, prompting clinical interest in this strategy. However, treatment outcomes vary across studies, and a systematic assessment of the efficacy and safety of cadonilimab plus chemotherapy remains limited. This study aimed to evaluate the efficacy and safety profile of cadonilimab in combination with chemotherapy for gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (G/GEJ adenocarcinoma) through a single-arm meta-analysis. A systematic search was conducted in PubMed, Embase, the Cochrane Library, Web of Science, and ClinicalTrials.gov to identify eligible studies published up to July 20, 2025. A single-arm meta-analysis was performed to pool and evaluate the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), pathological complete response (pCR), and the incidence of grade ≥3 treatment-related adverse events (TRAEs). A total of four clinical studies involving 182 patients were included. The pooled estimates were an ORR of 57% (95% CI: 48%-66%), a DCR of 97% (95% CI: 84%-100%), a pCR of 23% (95% CI: 12%-35%), and a median PFS of 7.98 months (95% CI: 6.38-9.57). The overall incidence of grade ≥3 TRAEs was 35% (95% CI: 7%-63%). In subgroup analyses, the incidence of grade ≥3 TRAEs appeared lower in the neoadjuvant setting than in the first-line setting (29% [95% CI: 28%-40%] vs 53% [95% CI: 45%-60%]). The most frequently reported adverse events included nausea (72%), vomiting (60%), neutropenia (51%), and leukopenia (45%). Based on available early-phase evidence, cadonilimab plus chemotherapy showed antitumor activity with a manageable safety profile in G/GEJ adenocarcinoma. Further large-scale, high-quality randomized controlled trials are needed to validate these findings and define the optimal treatment strategy. https://www.crd.york.ac.uk/PROSPERO, identifier CRD420251089855.
Is pathological complete response a surrogate for overall survival in neoadjuvant clinical trials for gastroesophageal adenocarcinoma?
Pathologic complete response (pCR) is frequently used as a surrogate endpoint in neoadjuvant gastroesophageal adenocarcinoma (GEA) trials, yet its validity in predicting overall survival (OS) remains uncertain. This systematic review and meta-analysis, follows PRISMA and ReSEEM guidelines, and evaluates pCR as a surrogate for OS in randomized controlled trials (RCTs) of neoadjuvant therapy for GEA. Randomized trials enrolling patients with resectable distal esophageal, gastroesophageal junction (GEJ), or gastric adenocarcinoma were included if both pCR and OS were reported. Individual-level surrogacy was assessed by correlating pCR rates with median OS across trial arms; trial-level surrogacy was evaluated by correlating treatment effects on pCR (odds ratios) with treatment effects on OS (hazard ratios) using weighted linear regression and calculating the coefficient of determination (R²). Twenty-six RCTs including 7452 patients were analyzed. Overall, pCR showed no meaningful correlation with OS at the individual-level (R² = 0.006; p = 0.210), and treatment effects on pCR explained little of the variability in OS effects at the trial level (R² = 0.060; p = 0.206). Most trials evaluated cytotoxic chemotherapy or chemoradiotherapy. Surrogacy varied by subgroup, being strong for esophageal adenocarcinoma (R² = 0.886; p < 0.001), moderate for gastric cancer (R² = 0.386; p = 0.041), and absent for GEJ trials. Trials incorporating radiotherapy demonstrated strong surrogacy, whereas chemotherapy-only trials did not. The interpretation of pCR results in gastroesophageal adenocarcinoma trials requires caution. Surrogacy might need to be reassessed in the upcoming immunotherapy trials.
Publicações recentes
Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.
Efficacy and safety of cadonilimab combined with chemotherapy for gastric or gastroesophageal junction adenocarcinoma: a single-arm meta-analysis.
Is pathological complete response a surrogate for overall survival in neoadjuvant clinical trials for gastroesophageal adenocarcinoma?
Cost-effectiveness of perioperative durvalumab plus FLOT for resectable gastric and gastroesophageal junction adenocarcinoma in the United States.
Early Recurrence of Esophagogastric junction adenoCarcinoma after Surgery: a multicentre analysis of risk factors (ERECS Trial).
📚 EuropePMC10 artigos no totalmostrando 198
Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: Current Status, Challenges, and Future Perspectives.
Cancer medicineCamrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.
BMJ (Clinical research ed.)Efficacy and safety of cadonilimab combined with chemotherapy for gastric or gastroesophageal junction adenocarcinoma: a single-arm meta-analysis.
Frontiers in immunologyIs pathological complete response a surrogate for overall survival in neoadjuvant clinical trials for gastroesophageal adenocarcinoma?
European journal of cancer (Oxford, England : 1990)Cost-effectiveness of perioperative durvalumab plus FLOT for resectable gastric and gastroesophageal junction adenocarcinoma in the United States.
Frontiers in immunologyEarly Recurrence of Esophagogastric junction adenoCarcinoma after Surgery: a multicentre analysis of risk factors (ERECS Trial).
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractThe Evolving Paradigm of Esophageal and Esophagogastric Junction Adenocarcinoma: Current Insights, Emerging Therapies, and Future Directions.
Journal of cancer science and clinical therapeuticsTreatment patterns, health care resource utilization and costs, and clinical outcomes among older adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Journal of managed care & specialty pharmacyOcular Safety Evaluation of Bemarituzumab in FGFR2b-Overexpressing Gastroesophageal Adenocarcinoma: A 42-Week Follow-Up Study.
Ocular immunology and inflammationClonal cell states link gastroesophageal junction tissues with metaplasia and cancer.
Nature communicationsComparative short-term outcomes of peri-operative immunotherapy and targeted therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyRisk factors and prediction model for submucosal invasion in early protruding-type esophagogastric junction adenocarcinoma: conventional endoscopy combines with endoscopic ultrasonography.
BMC gastroenterologyDoes perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis.
British journal of cancerThe Relevance of Lymphadenectomy Extension to the Right Paratracheal Space in the Treatment of Esophagogastric Junction Adenocarcinoma: A Retrospective Bicentric Study.
Current oncology (Toronto, Ont.)Diagnostic Approach to Early Barrett's Neoplasia: Western Perspective.
DigestionToward standardization in esophageal cancer surgery: patterns of practice across high-volume European centers.
Diseases of the esophagus : official journal of the International Society for Diseases of the EsophagusCLDN18.2 expression in gastroesophageal adenocarcinoma: prevalence, heterogeneity, and prognostic implications in Spanish patients.
Virchows Archiv : an international journal of pathologyReal-world comparison between neoadjuvant FLOT therapy and DCF therapy for resectable esophagogastric junction adenocarcinoma.
Esophagus : official journal of the Japan Esophageal SocietyIntratumoral regulatory T cells are associated with treatment response to neoadjuvant chemotherapy and prognosis in gastroesophageal adenocarcinoma.
OncoimmunologyStrategies to prevent Barrett's esophagus associated esophageal adenocarcinoma.
World journal of gastroenterologyFirst-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial.
European journal of cancer (Oxford, England : 1990)Novel Methylation-Based Model for Accurate Diagnosis of Upper Mediastinal Lymph Node Metastasis in Esophagogastric Junction Adenocarcinoma.
Cancer sciencePerioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial.
Nature medicineBeamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers.
Future oncology (London, England)Comparison of Pretreatment Strategies for cT2cN0 Staged Adenocarcinoma of the Esophagus and the Gastroesophageal Junction: A European High-Volume Center Cohort Analysis.
Annals of surgical oncologyEndoscopic Evaluation of the Gastroesophageal Junction and Diagnosis of Barrett's Esophagus.
DigestionNear-Infrared Photoimmunotherapy Targeting Esophagogastric Junction Adenocarcinoma With Fully Human Anti-EpCAM Antibody.
Cancer scienceHuman Epidermal Growth Factor Receptor 2 [HER-2/neu] Amplification and Microsatellite Stable Status in Gastric and Gastroesophageal Adenocarcinoma: Assessing Frequency and Prognostic Implications at the Cancer Institute of Iran.
Cancer reports (Hoboken, N.J.)Claudin 18.2 and Other Therapeutic Biomarkers in Gastric and Gastroesophageal Junction Adenocarcinomas.
The American journal of surgical pathologyFLOT Versus CROSS-What Is the Optimal Therapeutic Approach for Locally Advanced Adenocarcinoma of the Esophagus and the Esophagogastric Junction?
CancersFirst-line pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the phase 3 KEYNOTE-859 study.
International journal of clinical oncologyLongitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study.
Nature communicationsAnalytical and Clinical Performance of the VENTANA CLDN18 (43-14A) RxDx Assay in Gastric and Gastroesophageal Junction Adenocarcinoma Tissue Samples in SPOTLIGHT and GLOW.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, IncEfficacy of perioperative and neoadjuvant therapies in gastric and gastroesophageal junction adenocarcinoma: a network meta-analysis.
The oncologistDKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.
Nature communicationsQ-TWiST analysis of first-line nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma from CheckMate 649: 4-year follow-up results.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationTislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study.
Current medical research and opinionCost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma.
Frontiers in immunologyZolbetuximab-clzb: Targeting Claudin 18.2 in Advanced Gastric and Gastroesophageal Adenocarcinoma.
The Annals of pharmacotherapyFirst-line immune checkpoint inhibitors with chemotherapy in advanced gastric and gastroesophageal junction adenocarcinoma: a meta-analysis of phase 3 trials.
Frontiers in immunologyRegorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58-UCGI35-REGIRI Unicancer randomised phase II study.
ESMO openZanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial.
Nature communicationsBiomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma.
Journal of the National Comprehensive Cancer Network : JNCCNDetection of Barrett's Esophagus Prior to Development of Esophageal and Esophagogastric Junction Adenocarcinoma.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationTFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial.
The Lancet. OncologyThe Impact of Peri-Operative Nutritional Status on Survival in Gastroesophageal Adenocarcinoma.
Current oncology (Toronto, Ont.)Long-term trends in the clinical management and outcomes of patients with gastroesophageal cancer in Norway.
Acta oncologica (Stockholm, Sweden)Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: A Phase II Study.
Cancer medicineGastric Cardiac Carcinoma: Recent Progress in Clinicopathology, Prognosis, and Early Diagnosis.
Journal of digestive diseasesAssociations between body mass index and gastroesophageal cancer incidence and mortality: novel insights from a nationwide registry-based cohort study.
Diseases of the esophagus : official journal of the International Society for Diseases of the EsophagusPrognostic significance of subcarinal lymph node involvement in patients with Siewert type I and II gastro-esophageal junctional adenocarcinoma: an analysis of 698 patients undergoing Ivor-Lewis esophagectomy.
Diseases of the esophagus : official journal of the International Society for Diseases of the EsophagusPerioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial.
Signal transduction and targeted therapyEffects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy).
BMC cancerIs it time to retire preoperative radiation for localized esophageal and gastro-esophageal adenocarcinoma?
The oncologistFirst-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
Nature medicineStudy on the metastatic mechanism of LINC00115 in adenocarcinoma of the Esophagogastric junction.
Human molecular geneticsCanadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma.
Current oncology (Toronto, Ont.)Expression of therapy target molecules in esophagogastric junction and Barrett's adenocarcinoma.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationTremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO.
Annals of oncology : official journal of the European Society for Medical OncologyNeoadjuvant cadonilimab plus FLOT chemotherapy in locally advanced gastric/gastroesophageal junction adenocarcinoma: A multicenter, phase 2 study.
Med (New York, N.Y.)[Claudine 18.2: A new therapeutic target in digestive cancers].
Bulletin du cancerMore May Not Be Better: Comparison of Oncologic Outcomes Following Induction Chemotherapy Plus Chemoradiation and Chemoradiation Alone for Esophageal Adenocarcinoma.
Journal of surgical oncologyAccuracy of the preoperative estimation of esophageal invasion length of adenocarcinoma of the esophagogastric junction and its discrepancy with the pathological measurement.
Surgery todayChemotherapy effects on mitochondrial function in adipose tissue in oesophageal and gastroesophageal junction adenocarcinomas with or without associated cachexia: protocol for a prospective, comparative observational study (ChiFMeOE).
BMJ openEvolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma.
Current oncology reportsFOXP3+/CD8+ ratio associated with aggressive behavior in RUNX3-methylated diffuse esophagogastric junction tumor.
Cancer scienceDKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish.
Journal of clinical oncology : official journal of the American Society of Clinical OncologyImmune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups.
ESMO openPD-1/PD-L1 Inhibitors in Combination With Chemo or as Monotherapy vs. Chemotherapy Alone in Advanced, Unresectable HER2-Negative Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Meta-Analysis.
Clinical oncology (Royal College of Radiologists (Great Britain))Tumor thickness is associated with metastasis in patients with submucosal invasive adenocarcinoma of the esophagogastric junction.
Diseases of the esophagus : official journal of the International Society for Diseases of the EsophagusCombination of immune checkpoint inhibitors and radiotherapy in locally advanced esophagogastric junction adenocarcinoma: A review.
CancerPredictors of early recurrence of oesophagogastric adenocarcinoma after neoadjuvant FLOT.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyClinical Trials in Gastroesophageal Cancers: An Analysis of the Global Landscape of Interventional Trials From ClinicalTrials.gov.
JCO global oncologyHealth-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials.
ESMO openClinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma.
Nature communicationsThe Landscape and Prognosis of Microsatellite Stable (MSS) Esophageal, Gastro-Esophageal Junction and Gastric Adenocarcinomas with High Tumor Mutation Burden (TMB).
Cancer investigationOptimal Treatment Strategies for cT2 Staged Adenocarcinoma of the Esophagus and the Gastroesophageal Junction: A Multinational, High-volume Center Retrospective Cohort Analysis.
Annals of surgeryEfficacy and safety of ramucirumab for gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis.
European journal of clinical pharmacologyClaudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, IncPreoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction: A Network Meta-Analysis.
JAMA network openCharacteristics of auto-quantified tumor-infiltrating lymphocytes and the prognostic value in adenocarcinoma of the esophagogastric junction, gastric adenocarcinoma, and esophageal squamous cell carcinoma.
AgingDiffuse-Type Histology Is Prognostic for All Siewert Types of Gastroesophageal Adenocarcinoma.
Journal of gastric cancerFruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial.
Nature medicineTislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.
BMJ (Clinical research ed.)Histopathologic response in patients with curative resection with D2 dissection following neoadjuvant treatment for locally advanced gastric and esophagogastric junction adenocarcinoma.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyTrifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the LiverChallenges and considerations in interpreting the age-dependent benefit of neoadjuvant treatment for adenocarcinoma of the esophagus and gastroesophageal junction.
International journal of surgery (London, England)Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer.
Cancer research communicationsPhenotypic immune characterization of gastric and esophageal adenocarcinomas reveals profound immune suppression in esophageal tumor locations.
Frontiers in immunologyReal-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review.
Advances in therapy[High LINC00626 expression promotes esophagogastric junction adenocarcinoma metastasis: the mediating role of the JAK1/STAT3/KHSRP axis].
Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityA prospective phase II clinical trial of total neoadjuvant therapy for locally advanced gastric cancer and gastroesophageal junction adenocarcinoma.
Scientific reportsSiewert II esophagogastric junction adenocarcinoma: Still searching for the right treatment transabdominal or transthoracic surgical approaches?
Asian cardiovascular & thoracic annalsEsophageal adenocarcinoma heterogeneity in clinicopathology and prognosis: A single center longitudinal study of 146 cases over a 20-year period.
Annals of diagnostic pathologyPreoperative ultrasound-guided dual localization with titanium clips and carbon nanoparticles for predicting the surgical approach and guiding the resection of Siewert type II esophagogastric junction adenocarcinoma.
Journal of cancer research and clinical oncologyPreoperative docetaxel, cisplatin, and 5-fluorouracil for resectable locally advanced esophageal and esophagogastric junctional adenocarcinoma.
Esophagus : official journal of the Japan Esophageal SocietyPerioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationEndoscopic Characteristics of Early Gastroesophageal Junction Adenocarcinomas and Assessment for Invasion Depth: A Case Series Study.
The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyMulticenter analysis on the value of standard (chemo)radiotherapy in elderly patients with locally advanced adenocarcinoma of the esophagus or gastroesophageal junction.
Radiation oncology (London, England)[Interpretation of Chinese expert consensus on the surgical treatment for adenocarcinoma of esophagogastric junction(2024 edition)].
Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery[Chinese expert consensus on the surgical treatment for adenocarcinoma of esophagogastric junction (Edition 2024)].
Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgeryA proactive financial navigation intervention in patients with newly diagnosed gastric and gastroesophageal junction adenocarcinoma.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerTumor stroma ratio, tumor stroma maturity, tumor-infiltrating immune cells in relation to prognosis, and neoadjuvant therapy response in esophagogastric junction adenocarcinoma.
Virchows Archiv : an international journal of pathologyEfficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials.
BMC cancerFirst-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
Journal of clinical oncology : official journal of the American Society of Clinical OncologyFruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol.
BMJ openBemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationAssociations of long non-coding RNAs HOTAIR, LINC00951, POLR2E and HULC polymorphisms with the risk of esophageal and esophagogastric junction cancer in a western population: a case-control study.
Molecular biology reportsUpdated German guideline on diagnosis and treatment of squamous cell carcinoma and adenocarcinoma of the esophagus.
United European gastroenterology journalCurrent and Future Biomarkers in Esophagogastric Adenocarcinoma.
Journal of gastrointestinal cancerEndoscopic Surveillance of Intestinal Metaplasia of the Esophagogastric Junction: A Decision Modeling Analysis.
The American journal of gastroenterology[Comparison of short-term safety of two anastomotic techniques when resecting Siewert type II adenocarcinoma of the esophagogastric junction: a multicenter retrospective cohort study].
Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgeryEarly endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study).
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationManagement of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS trial - Authors' reply.
The lancet. Gastroenterology & hepatologyManagement of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS trial.
The lancet. Gastroenterology & hepatologyNeoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.
Nature medicineNCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
British journal of cancerClinical features and outcomes of advanced HER2+ esophageal/GEJ cancer with brain metastasis.
ESMO open[Pembrolizumab with trastuzumab and chemotherapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinomas with surexpression of HER2 and CPS≥1].
Bulletin du cancerEfficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study).
Frontiers in immunologyEffect of different surgical approaches on the survival and safety of Siewert type II esophagogastric junction adenocarcinoma: a systematic review and meta-analysis.
BMC cancerProtocol digest of a randomized controlled adaptive Phase II/III trial of neoadjuvant chemotherapy for Japanese patients with oesophagogastric junction adenocarcinoma: Japan Clinical Oncology Group Study JCOG2203 (NEO-JPEG).
Japanese journal of clinical oncologyConcise Commentary: It's All Downhill from Here-How Diagnostic and Therapeutic Advances May Decrease the Incidence Rates of Gastroesophageal Junction and Esophageal Adenocarcinoma.
Digestive diseases and sciencesPopulation Based Time Trends in the Epidemiology and Mortality of Gastroesophageal Junction and Esophageal Adenocarcinoma.
Digestive diseases and sciencesHistology Shift in Esophageal Cancer Between Biopsies and Resections After Neoadjuvant Therapy: A Pilot Study.
International journal of surgical pathologyTotal neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma.
British journal of cancerChemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma.
JAMA oncologyThe correlation between the margin of resection and prognosis in esophagogastric junction adenocarcinoma.
World journal of surgical oncologyDiagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.
EndoscopyNivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: Analysis of Number Needed To Treat and Number Needed To Harm.
Clinical therapeuticsRelationship between the number of dissected lymph node and the pathological staging in esophagogastric junction adenocarcinoma.
Asian journal of surgeryTrimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial.
The lancet. Gastroenterology & hepatologyCost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan.
Journal of gastroenterologyAge-dependent benefit of neoadjuvant treatment in adenocarcinoma of the esophagus and gastroesophageal junction: a multicenter retrospective observational study of young versus old patients.
International journal of surgery (London, England)Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.
Journal of clinical oncology : official journal of the American Society of Clinical OncologyHer2 low (but not negative): the newest biomarker on the block for gastro-oesophageal adenocarcinoma.
Journal of clinical pathology[A Case of Advanced Esophagogastric Junction Adenocarcinoma with Enlarged Lymph Node Metastases of the Middle Mediastinum and Intraperitoneal That Exhibited pCR by Preoperative SOX Therapy].
Gan to kagaku ryoho. Cancer & chemotherapyClinical characteristics and prognostic outcomes for adenocarcinoma of esophagogastric junction in early-onset patients: a population-based appraisal.
Journal of cancer research and clinical oncologyRandomized controlled trial in gastric or gastroesophageal junction adenocarcinoma undergoing systemic therapy over two decades.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyNeoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial.
Nature communicationsRandomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).
BMC cancerHistology-Based Prediction of Therapy Response to Neoadjuvant Chemotherapy for Esophageal and Esophagogastric Junction Adenocarcinomas Using Deep Learning.
JCO clinical cancer informaticsZolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
Nature medicineImpact of the Surgical Approach for Neoadjuvantly Treated Gastroesophageal Junction Type II Tumors: A Multinational, High-volume Center Retrospective Cohort Analysis.
Annals of surgeryNovel Staging Schemes for Siewert Type II Esophagogastric Junction Adenocarcinoma: A Real-World Data Cohort Study from SEER Database.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer ResearchSerum Interleukin 6 Level is Associated With Overall Survival and Treatment Response in Gastric and Gastroesophageal Junction Cancer.
Annals of surgery[Efficacy of machine learning models versus Cox regression model for predicting prognosis of esophagogastric junction adenocarcinoma].
Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityNomogram for predicting the likelihood of liver metastases at initial diagnosis in patients with Siewert type II gastroesophageal junction adenocarcinoma.
Scientific reportsIncidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma.
ESMO openRamucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415).
BMC cancerEfficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis.
ChemotherapyA phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.
Cancer medicineAccurate Preoperative Evaluation of the Location of Esophagogastric Junction Adenocarcinoma Using Positron Emission Tomography-Computed Tomography.
The American surgeonFLOT or CROSS for gastroesophageal junction cancers-is the debate over yet?
Chinese clinical oncologyAdvancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers.
ImmunotherapyPreoperative chemoradiotherapy or perioperative chemotherapy for patients with gastro-oesophageal junction adenocarcinoma.
The Lancet. OncologyExtension of resection after positive intraoperative pathology during surgery for gastric and gastroesophageal junction adenocarcinoma: a retrospective cohort study.
International journal of surgery (London, England)Long-Term Postsurgical Outcomes of Neoadjuvant Chemoradiation (CROSS) Versus Chemotherapy (FLOT) for Multimodal Treatment of Adenocarcinoma of the Esophagus and the Esophagogastric Junction.
Annals of surgical oncologyAtypical presentation in adolescence of a gastroesophageal junction adenocarcinoma.
Revista de gastroenterologia de Mexico (English)Relevance of Subcarinal Lymph Node Dissection for Gastroesophageal Junction Adenocarcinoma.
The Journal of surgical researchSafety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.
BMC medicineDetection of a Novel MSI2-C17orf64 Transcript in a Patient with Aggressive Adenocarcinoma of the Gastroesophageal Junction: A Case Report.
GenesArtificial intelligence for tumour tissue detection and histological regression grading in oesophageal adenocarcinomas: a retrospective algorithm development and validation study.
The Lancet. Digital healthHand-sewn esophagojejunostomy in transthoracic single-port assisted laparoscopic esophagogastrectomy for Siewert type II adenocarcinoma of the esophagogastric junction with esophageal invasion > 3 cm.
Surgical endoscopy[Feasibility of a single-port thoracoscopy-assisted five-step laparoscopic procedure via transabdominal diaphragmatic approach for No.111 lymphadenectomy in patients with Siewert type II esophageal gastric junction adenocarcinoma].
Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgeryZolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Lancet (London, England)HER2-low in gastro-oesophageal adenocarcinoma: a real-world pathological perspective.
Journal of clinical pathologyNeoadjuvant Management of Adenocarcinoma of the Esophagus and Esophagogastric Junction: Review of Randomized Evidence and Definition of Optimum Treatment Algorithm.
OncologyA Nomogram Based on Nutrition-Related Indicators and Computed Tomography Imaging Features for Predicting Preoperative Lymph Node Metastasis in Curatively Resected Esophagogastric Junction Adenocarcinoma.
Annals of surgical oncologyThe effectiveness of neoadjuvant chemoradiotherapy in oesophageal adenocarcinoma with presence of extracellular mucin, signet-ring cells, and/or poorly cohesive cells.
The journal of pathology. Clinical researchPatients with esophageal adenocarcinoma showed better prognosis than those with adenocarcinoma of the gastroesophageal junction.
Journal of digestive diseasesQuality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationHigh Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, IncSintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial.
BMC cancerPhase II clinical trial of sequential treatment with systemic chemotherapy and intraperitoneal paclitaxel for gastric and gastroesophageal junction peritoneal carcinomatosis - STOPGAP trial.
BMC cancerGlobal retrospective analysis of clinician- and patient-reported clinical characteristics and humanistic burden of patients with gastroesophageal cancers on first-line treatment.
BMC cancerParaconduit hernia after minimally invasive esophagectomy - incidence and risk factors.
Scandinavian journal of gastroenterologyYield of Repeat Endoscopy for Barrett's Esophagus After Normal Index Endoscopy.
The American journal of gastroenterologyEvent-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting.
Clinical cancer research : an official journal of the American Association for Cancer ResearchImmunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer.
Journal of cancer research and clinical oncologyImmunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
Journal of clinical oncology : official journal of the American Society of Clinical OncologyAcquired microsatellite instability status and loss of HER2 positivity during treatment of gastro-esophageal junction adenocarcinoma.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the LiverPembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.
Japanese journal of clinical oncologyCytopathological features of gastroesophageal junction adenocarcinoma with enteroblastic differentiation and histopathological correlation.
Cytopathology : official journal of the British Society for Clinical CytologyPhase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma.
Cancer scienceDaily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort.
Cancer medicinePhase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma.
Cell reports. MedicineTrastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
Journal of clinical oncology : official journal of the American Society of Clinical OncologyThe optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis.
European journal of medical researchOngoing Controversies in Esophageal Cancer II: Gastrectomy versus Esophagectomy for Siewert Type II Esophageal Adenocarcinoma.
Thoracic surgery clinicsBemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.
The Lancet. OncologyPerioperative Modified FLOT Versus EOX in Locally Advanced Resectable Gastric and Gastro-Oesophageal Junction Adenocarcinoma: Results of a Matched-Pair Analysis.
Journal of gastrointestinal cancerSafety and efficacy of preoperative indocyanine green fluorescence marking in laparoscopic gastrectomy for proximal gastric and esophagogastric junction adenocarcinoma (ICG MAP study).
Langenbeck's archives of surgeryAdenocarcinoma of the stomach and esophagogastric junction with low DNA methylation show poor prognoses.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationComparison of short-term surgical outcomes between complete mesenteric resection and traditional transhiatal laparoscopic surgery for Siewert type II/III esophagogastric junction adenocarcinoma.
Langenbeck's archives of surgeryRecent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction.
World journal of gastroenterologyAI-assisted discovery of an ethnicity-influenced driver of cell transformation in esophageal and gastroesophageal junction adenocarcinomas.
JCI insightAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Adenocarcinoma do esôfago.
É de uma associação que acompanha esta doença? Fale com a gente →
Doença com base genética
Um médico geneticista pode ajudar no diagnóstico de Adenocarcinoma do esôfago e no aconselhamento genético da família.
Doenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Perguntas frequentes
O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu
Trata-se de um tumor maligno de células glandulares localizado principalmente no terço inferior do esôfago. Ele costuma desenvolver-se a partir de lesões prévias na mucosa, sobretudo associadas ao esôfago de Barrett.
Referências
Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete
7 publicações do grafo RarasNet (PubMed) · 5 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Citar este verbete
Raras. (s.d.). Adenocarcinoma do esôfago. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/adenocarcinoma-do-esofago
Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
Adenocarcinoma do esôfago
📋 Origem dos dados
Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.
- Doença rara (ontologia)
- fonte: Orphanet
- Identificador unificado
- fonte: MONDO
- Codificação WHO/SUS
- fonte: WHO ICD-10 / DATASUS
- CID-11 (futuro)
- fonte: WHO ICD-11
- NIH/GARD
- fonte: GARD (NIH)
- Indexação biomédica
- fonte: MeSH (NLM)
- Dado público estruturado
- fonte: Wikidata
- Medicamentos aprovados FDA
- fonte: FDA OpenFDA
- Ensaios clínicos
- fonte: ClinicalTrials.gov